
Edgar Filing: Akebia Therapeutics, Inc. - Form 4

Akebia Therapeuti Form 4	ics, Inc.								
June 20, 2016									
FORM 4									PPROVAL
	UNITED	STATES		RITIES A Ashington			COMMISSIO	N OMB Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5			F CHAI	NGES IN SECUI	WNERSHIP O	Expires: Estimated burden ho response.	urs per		
obligations may continue. <i>See</i> Instruction 1(b).	-	(a) of the l	Public U	Jtility Hol	ding Con		of 1935 or Sect		
(Print or Type Respon	ses)								
1. Name and Address of Reporting Person <u>*</u> Satter Muneer A		2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer				
				1 Therapet		[AKBA]	(Ch	eck all applicabl	le)
(Last) (F C/O AKEBIA TH INC., 245 FIRST 1100	IERAPEUT			of Earliest T Day/Year) 2016	ransaction		Director Officer (gi below)		% Owner her (specify
(S CAMBRIDGE, M	(IA 02142			endment, D onth/Day/Yea	-	l	Applicable Line) _X_ Form filed b	Joint/Group Fili y One Reporting F y More than One R	Person
(City) (S	State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned
	nsaction Date h/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	4. Securiti nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Report on a	a separate line	e for each cl	ass of sec	urities bene	ficially owr	ed directly o	or indirectly		
reminder. report on t	a separate mix			unites bene	Person inform require	ns who rest ation cont ed to respo ys a curre	spond to the colle ained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)
	Tab					posed of, or convertible s	Beneficially Owne securities)	d	
1. Title of 2.	3. Trans	saction Date	3A. Dee	emed	4.	5. Number	of 6. Date Exerc	isable and	7. Title and

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Akebia Therapeutics, Inc. - Form 4



Signatures

Jon-Micheal A. Wheat, attorney-in-fact for Muneer A. Satter

06/20/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

100% of the option shares vest on the earlier of June 16, 2017 or the date immediately prior to the next annual meeting of the Issuer after the grant date (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board(1) of Directors through the applicable Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for

vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.